Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) Short Interest Down 51.5% in May

Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) saw a significant drop in short interest in May. As of May 29th, there was short interest totaling 10,140 shares, a drop of 51.5% from the May 14th total of 20,907 shares. Based on an average daily trading volume, of 16,983 shares, the short-interest ratio is presently 0.6 days. Approximately 0.5% of the shares of the stock are short sold.

Biodexa Pharmaceuticals Stock Down 1.6%

BDRX traded down $0.05 during trading on Friday, reaching $3.03. The stock had a trading volume of 12,105 shares, compared to its average volume of 22,841. The business has a 50-day moving average of $3.52 and a 200-day moving average of $8.76. Biodexa Pharmaceuticals has a one year low of $2.86 and a one year high of $66.50.

Biodexa Pharmaceuticals (NASDAQ:BDRX) last announced its quarterly earnings data on Friday, March 27th. The company reported $3.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.01) by $3.53.

Analysts Set New Price Targets

A number of brokerages recently issued reports on BDRX. Wall Street Zen downgraded Biodexa Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, March 30th. Weiss Ratings downgraded Biodexa Pharmaceuticals from a “sell (e+)” rating to a “sell (e)” rating in a research report on Wednesday, June 3rd. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has an average rating of “Sell”.

Institutional Trading of Biodexa Pharmaceuticals

An institutional investor recently bought a new position in Biodexa Pharmaceuticals stock. Sabby Management LLC acquired a new position in Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 190,658 shares of the company’s stock, valued at approximately $433,000. Biodexa Pharmaceuticals accounts for 0.6% of Sabby Management LLC’s holdings, making the stock its 10th largest holding. Sabby Management LLC owned 28.04% of Biodexa Pharmaceuticals at the end of the most recent reporting period. Institutional investors own 17.51% of the company’s stock.

Biodexa Pharmaceuticals Company Profile

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease.